| Investigational treatments in phase I and II clinical trials: a systematic review in asthma L Calzetta, M Aiello, A Frizzelli, E Pistocchini, BL Ritondo, P Rogliani, ... Biomedicines 10 (9), 2330, 2022 | 7 | 2022 |
| Pharmacological characterization of the anti-inflammatory effect of mepolizumab and benralizumab in a human ex vivo model of asthma P Rogliani, F Facciolo, E Melis, BL Ritondo, MC Gabriele, A Perduno, ... European Respiratory Journal 60 (suppl 66), 2022 | | 2022 |
| LPS-challenged equine bronchi: evidence for IL-6 as a target against AHR L Calzetta, E Pistocchini, G Cito, BL Ritondo, S Verri, P Rogliani European Respiratory Journal 60 (suppl 66), 2022 | | 2022 |
| Sex differences in adult asthma and COPD therapy: a systematic review P Rogliani, F Cavalli, BL Ritondo, M Cazzola, L Calzetta Respiratory Research 23 (1), 222, 2022 | 13 | 2022 |
| Impact of sex on proper use of inhaler devices in asthma and COPD: a systematic review and meta-analysis L Calzetta, M Aiello, A Frizzelli, BL Ritondo, E Pistocchini, P Rogliani, ... Pharmaceutics 14 (8), 1565, 2022 | 5 | 2022 |
| The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review L Calzetta, BL Ritondo, MC Zappa, GM Manzetti, A Perduno, J Shute, ... European Respiratory Review 31 (164), 2022 | 12 | 2022 |
| Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models L Calzetta, E Pistocchini, BL Ritondo, F Cavalli, F Camardelli, P Rogliani Heliyon 8 (6), 2022 | 2 | 2022 |
| Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma L Calzetta, E Pistocchini, G Cito, BL Ritondo, S Verri, P Rogliani Pulmonary Pharmacology & Therapeutics 73, 102125, 2022 | 6 | 2022 |
| Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies L Calzetta, BL Ritondo, MG Matera, A Chetta, P Rogliani Expert Review of Respiratory Medicine 16 (3), 357-365, 2022 | 7 | 2022 |
| Pulmonary rehabilitation in noncystic fibrosis bronchiectasis J Ora, E Prendi, BL Ritondo, X Pata, F Spada, P Rogliani Respiration 101 (1), 97-105, 2022 | 7 | 2022 |
| Current long-acting muscarinic antagonists for the treatment of asthma J Ora, L Calzetta, BL Ritondo, MG Matera, P Rogliani Expert Opinion on Pharmacotherapy 22 (17), 2343-2357, 2021 | 2 | 2021 |
| Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: a systematic review P Rogliani, BL Ritondo, E Puxeddu, M Cazzola, L Calzetta Respiratory Medicine 189, 106639, 2021 | 4 | 2021 |
| Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways P Rogliani, BL Ritondo, F Facciolo, MG Matera, I Nikolaev, L Calzetta Pharmacological Research 172, 105801, 2021 | 17 | 2021 |
| The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review L Calzetta, M Aiello, A Frizzelli, G Bertorelli, BL Ritondo, P Rogliani, ... Biomedicines 9 (9), 1281, 2021 | 15 | 2021 |
| Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release P Rogliani, BL Ritondo, F Facciolo, MG Matera, I Nikolaev, L Calzetta European Respiratory Journal 58 (suppl 65), 2021 | | 2021 |
| Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies P Rogliani, BL Ritondo, L Calzetta European Respiratory Journal 58 (3), 2021 | 50 | 2021 |
| Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile L Calzetta, B Ludovica Ritondo, P de Marco, M Cazzola, P Rogliani Expert Review of Respiratory Medicine 15 (4), 579-581, 2021 | 3 | 2021 |
| Factors influencing the efficacy of COVID-19 vaccines: a quantitative synthesis of phase III trials L Calzetta, BL Ritondo, A Coppola, MG Matera, N Di Daniele, P Rogliani Vaccines 9 (4), 341, 2021 | 33 | 2021 |
| Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review BL Ritondo, E Puxeddu, L Calzetta, M Cazzola, P Rogliani Expert opinion on pharmacotherapy 22 (5), 611-620, 2021 | 11 | 2021 |
| The impact of muscarinic receptor antagonists on airway inflammation: a systematic review L Calzetta, A Coppola, BL Ritondo, M Matino, A Chetta, P Rogliani International Journal of Chronic Obstructive Pulmonary Disease, 257-279, 2021 | 23 | 2021 |
